Search research articles
Contact Us
Filters
Showing results (41-50 of 103) with videos related to
Page
of 11
Sort By:
Journal of Hematology & Oncology
|
November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Brian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy
Thomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.
Pediatric Blood & Cancer
|
June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
Wei Wei, Maggie Eidson Fader, Brian H Kushner, et al.
Pediatric Blood & Cancer
|
January 28, 2021
Mandibular metastases in neuroblastoma: Outcomes and dental sequelae
Annu Singh, Shakeel Modak, Armand K Solano, et al.
Pediatric Blood & Cancer
|
February 23, 2018
Dose-escalation is needed for gross disease in high-risk neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Pediatric Blood & Cancer
|
June 17, 2020
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience
Ami Patel, Cheryl Fischer, Yi-Chih Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
Nai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Vaccines
|
June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine
Irene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Oncoimmunology
|
November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival
Irene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 31, 2016
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 103) with videos related to
Sort By:
Page
of 11
Journal of Hematology & Oncology
|
November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Brian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy
Thomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.
Pediatric Blood & Cancer
|
June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
Wei Wei, Maggie Eidson Fader, Brian H Kushner, et al.
Pediatric Blood & Cancer
|
January 28, 2021
Mandibular metastases in neuroblastoma: Outcomes and dental sequelae
Annu Singh, Shakeel Modak, Armand K Solano, et al.
Pediatric Blood & Cancer
|
February 23, 2018
Dose-escalation is needed for gross disease in high-risk neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Pediatric Blood & Cancer
|
June 17, 2020
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience
Ami Patel, Cheryl Fischer, Yi-Chih Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
Nai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Vaccines
|
June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine
Irene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Oncoimmunology
|
November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival
Irene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 31, 2016
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Page
of 11